In addition, germ-free mice with melanoma that received fecal microbiota transplant (FMT) from melanoma patients with a strong response to CTLA-4 had better outcomes after treatment with ICIs as compared to those with FMT from non-responder patients, with the former group favoring the growth of B. fragilis [37]. Here, CTLA4 is linked to melanoma.